

# Hesai Group (HSAI US)

## Takeaway from 2026 Investor Day & Technology Open Day

We attended Hesai Group (Hesai)'s 2026 Investor Day and Technology Open Day. During the events, Hesai: 1) unveiled Picasso SPAD-SoC, the world's first 6D full-color LiDAR ultra-sensitive chip, and announced the ETX series LiDAR will be fully upgraded with the Picasso SPAD-SoC, supporting up to 4,320 lines of full-color 4K ultra-high-definition perception, with mass production and delivery scheduled for 2H26; 2) announced a strategic upgrade from "spatial perception" to "spatial intelligence", and showcased Kosmo, a spatial intelligence AI hardware product, which is expected to be officially launched in 2H26; 3) announced expansion into the new business field of robot power modules, viewing it as one of the core infrastructures of the physical AI era. Regarding business deployment on becoming a key enabler in physical AI era, Hesai will focus on enhancing immersive interactive experiences in the first phase, while the second phase will be dedicated to enabling physical AI training. We rate BUY on Hesai with a target price of US\$29.3 based on 7.5x 2026E P/S.

- **Picasso: achieves the fusion of color perception and distance measurement at the hardware level.** Picasso SPAD-SoC supports up to 4,320 laser channels and 4K ultra-high-definition perception. According to Hesai, the photon detection efficiency (PDE) of Picasso has exceeded 40%, reaching an industry-leading level. The new ETX LiDAR, powered by the Picasso chip, will integrate spatial and color detection, and is expected to enter mass production in 2H26.
- **Kosmo: targets to support the development of physical AI systems.** Kosmo is designed to collect real-world 3D data for creating "digital twins" of physical spaces. The device aims to support the development of physical AI systems, including humanoid robots, by enabling a better understanding in real-world environments. The product will initially focus on small business customers, before targeting the broader consumer market over the medium to long term, supported by scale effects and lower supply-chain costs.
- **TP of US\$29.3 based on 7.5x 2026E P/S.** For 2026E, we expect 101%/46% YoY growth in LiDAR shipment volume/total revenue for Hesai. Key catalysts include: 1) faster-than-expected adoption of L3 vehicles, which could increase LiDAR units per vehicle and drive higher dollar content per car; 2) ramp-up in physical AI-related product revenue and increasing contribution from international ADAS expansion.

### Earnings Summary

| (YE 31 Dec)                  | FY24A   | FY25A | FY26E | FY27E   | FY28E   |
|------------------------------|---------|-------|-------|---------|---------|
| Revenue (RMB mn)             | 2,077   | 3,028 | 4,407 | 6,016   | 8,019   |
| YoY growth (%)               | 10.7    | 45.8  | 45.6  | 36.5    | 33.3    |
| Net profit (RMB mn)          | (102.4) | 435.9 | 507.6 | 913.6   | 1,393.0 |
| Adjusted net profit (RMB mn) | 13.7    | 550.5 | 657.5 | 1,055.5 | 1,533.9 |
| EPS (Adjusted) (RMB)         | 0.11    | 3.96  | 4.04  | 6.56    | 9.53    |
| Consensus EPS (RMB)          | na      | 3.96  | 3.97  | 6.36    | 10.16   |

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Maintain)**

Target Price **US\$29.30**  
Up/Downside **26.0%**  
Current Price **US\$23.25**

### China Software & IT Services

**Saiyi HE, CFA**  
(852) 3916 1739  
hesaiyi@cmbi.com.hk

**Ye TAO, CFA**  
(852) 3850 5226  
franktao@cmbi.com.hk

**Wentao LU, CFA**  
luwentao@cmbi.com.hk

**Shuyin GUO**  
(852) 3916 3716  
guoshuyin@cmbi.com.hk

### Stock Data

|                          |             |
|--------------------------|-------------|
| Mkt Cap (US\$ mn)        | 3,742.7     |
| Avg 3 mths t/o (US\$ mn) | 39.3        |
| 52w High/Low (US\$)      | 29.80/11.61 |
| Total Issued Shares (mn) | 161.0       |

Source: FactSet

### Shareholding Structure

|                     |      |
|---------------------|------|
| Fermat Star Limited | 6.1% |
| Galbadia Limited    | 5.9% |


Source: NASDAQ

### Share Performance

|       | Absolute | Relative |
|-------|----------|----------|
| 1-mth | -5.4%    | -13.1%   |
| 3-mth | -18.6%   | -21.7%   |
| 6-mth | 3.6%     | -4.0%    |

Source: FactSet

### 12-month Price Performance



Source: FactSet

Figure 1: Hesai: Picasso SPAD-SoC



Source: Company data, CMBIGM

Figure 2: Hesai: customer list in Humanoid robot industry



Source: Company data, CMBIGM

## Financial Summary

| INCOME STATEMENT                     | 2023A          | 2024A          | 2025A          | 2026E          | 2027E          | 2028E          |
|--------------------------------------|----------------|----------------|----------------|----------------|----------------|----------------|
| YE 31 Dec (RMB mn)                   |                |                |                |                |                |                |
| <b>Revenue</b>                       | <b>1,877</b>   | <b>2,077</b>   | <b>3,028</b>   | <b>4,407</b>   | <b>6,016</b>   | <b>8,019</b>   |
| Cost of goods sold                   | (1,216)        | (1,193)        | (1,762)        | (2,666)        | (3,669)        | (4,928)        |
| Others                               | 0              | 0              | 0              | 0              | 0              | 0              |
| <b>Gross profit</b>                  | <b>661</b>     | <b>885</b>     | <b>1,265</b>   | <b>1,741</b>   | <b>2,347</b>   | <b>3,091</b>   |
| <b>Operating expenses</b>            | <b>(1,233)</b> | <b>(1,089)</b> | <b>(1,096)</b> | <b>(1,288)</b> | <b>(1,361)</b> | <b>(1,439)</b> |
| Selling expense                      | (149)          | (193)          | (192)          | (221)          | (232)          | (243)          |
| SG&A expense                         | (320)          | (317)          | (289)          | (332)          | (349)          | (366)          |
| R&D expense                          | (791)          | (856)          | (797)          | (916)          | (962)          | (1,010)        |
| Others                               | 27             | 276            | 181            | 181            | 181            | 181            |
| <b>Operating profit</b>              | <b>(572)</b>   | <b>(205)</b>   | <b>169</b>     | <b>453</b>     | <b>986</b>     | <b>1,652</b>   |
| <b>EBITDA</b>                        | <b>(485)</b>   | <b>(73)</b>    | <b>169</b>     | <b>585</b>     | <b>1,150</b>   | <b>1,844</b>   |
| Depreciation                         | 86             | 132            | 0              | 132            | 165            | 192            |
| Interest income                      | 100            | 104            | 130            | 179            | 149            | 109            |
| Interest expense                     | (3)            | (13)           | (19)           | (21)           | (21)           | (21)           |
| <b>Net Interest income/(expense)</b> | <b>97</b>      | <b>92</b>      | <b>111</b>     | <b>159</b>     | <b>129</b>     | <b>89</b>      |
| Foreign exchange gain/loss           | (0)            | 15             | 2              | 0              | 0              | 0              |
| Other income/expense                 | 0              | (2)            | 185            | 0              | 0              | 0              |
| <b>Pre-tax profit</b>                | <b>(475)</b>   | <b>(101)</b>   | <b>467</b>     | <b>612</b>     | <b>1,114</b>   | <b>1,741</b>   |
| Income tax                           | (1)            | (1)            | (31)           | (104)          | (201)          | (348)          |
| Others                               | 0              | 0              | 0              | 0              | 0              | 0              |
| <b>Net profit</b>                    | <b>(476)</b>   | <b>(102)</b>   | <b>436</b>     | <b>508</b>     | <b>914</b>     | <b>1,393</b>   |
| <b>Adjusted net profit</b>           | <b>(241)</b>   | <b>14</b>      | <b>551</b>     | <b>658</b>     | <b>1,056</b>   | <b>1,534</b>   |

| BALANCE SHEET                       | 2023A        | 2024A        | 2025A         | 2026E         | 2027E         | 2028E         |
|-------------------------------------|--------------|--------------|---------------|---------------|---------------|---------------|
| YE 31 Dec (RMB mn)                  |              |              |               |               |               |               |
| <b>Current assets</b>               | <b>4,398</b> | <b>4,683</b> | <b>7,069</b>  | <b>7,292</b>  | <b>8,470</b>  | <b>10,234</b> |
| Cash & equivalents                  | 3,141        | 3,246        | 4,850         | 4,659         | 4,970         | 5,651         |
| Account receivables                 | 525          | 765          | 1,262         | 1,475         | 2,014         | 2,685         |
| Inventories                         | 496          | 482          | 670           | 872           | 1,200         | 1,611         |
| Other current assets                | 236          | 190          | 286           | 286           | 286           | 286           |
| <b>Non-current assets</b>           | <b>872</b>   | <b>944</b>   | <b>944</b>    | <b>1,166</b>  | <b>1,293</b>  | <b>1,360</b>  |
| PP&E                                | 1,026        | 1,026        | 944           | 1,284         | 1,560         | 1,804         |
| Other non-current assets            | (154)        | (82)         | 0             | (117)         | (267)         | (444)         |
| <b>Total assets</b>                 | <b>5,663</b> | <b>5,990</b> | <b>11,261</b> | <b>11,701</b> | <b>12,927</b> | <b>14,712</b> |
| <b>Current liabilities</b>          | <b>1,335</b> | <b>1,629</b> | <b>1,895</b>  | <b>1,983</b>  | <b>2,295</b>  | <b>2,687</b>  |
| Short-term borrowings               | 112          | 345          | 448           | 448           | 448           | 448           |
| Account payables                    | 277          | 355          | 743           | 830           | 1,143         | 1,535         |
| Other current liabilities           | 947          | 929          | 704           | 704           | 704           | 704           |
| <b>Non-current liabilities</b>      | <b>465</b>   | <b>429</b>   | <b>407</b>    | <b>407</b>    | <b>407</b>    | <b>407</b>    |
| Long-term borrowings                | 286          | 269          | 279           | 279           | 279           | 279           |
| Other non-current liabilities       | 179          | 160          | 128           | 128           | 128           | 128           |
| <b>Total liabilities</b>            | <b>1,800</b> | <b>2,058</b> | <b>2,303</b>  | <b>2,390</b>  | <b>2,703</b>  | <b>3,095</b>  |
| Share capital                       | 7,424        | 7,577        | 11,926        | 11,926        | 11,926        | 11,926        |
| Retained earnings                   | (3,562)      | (3,645)      | (2,967)       | (2,615)       | (1,701)       | (308)         |
| Other reserves                      | 0            | 0            | 0             | 0             | 0             | 0             |
| <b>Total shareholders equity</b>    | <b>3,862</b> | <b>3,932</b> | <b>8,959</b>  | <b>9,311</b>  | <b>10,225</b> | <b>11,618</b> |
| Minority interest                   | 0            | 0            | 0             | 0             | 0             | 0             |
| <b>Total equity and liabilities</b> | <b>5,663</b> | <b>5,990</b> | <b>11,261</b> | <b>11,701</b> | <b>12,927</b> | <b>14,712</b> |

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report. CMBIGM or its affiliate(s) have investment banking relationship with the issuers covered in this report in preceding 12 months.

## CMBIGM Ratings

|                       |                                                                                                     |
|-----------------------|-----------------------------------------------------------------------------------------------------|
| <b>BUY</b>            | : Stock with potential return of over 15% over next 12 months                                       |
| <b>HOLD</b>           | : Stock with potential return of +15% to -10% over next 12 months                                   |
| <b>SELL</b>           | : Stock with potential loss of over 10% over next 12 months                                         |
| <b>NOT RATED</b>      | : Stock is not rated by CMBIGM                                                                      |
| <b>OUTPERFORM</b>     | : Industry expected to outperform the relevant broad market benchmark over next 12 months           |
| <b>MARKET-PERFORM</b> | : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months |
| <b>UNDERPERFORM</b>   | : Industry expected to underperform the relevant broad market benchmark over next 12 months         |

## CMB International Global Markets Limited

Address: 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.